Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model
The European Journal of Health Economics · 13.07.2026
DOI: 10.1007/s10198-026-01949-w ↗Kurz gefasst
Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 13.07.2026. Verfasst von Eleftherios Zarkadoulas und 4 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Av. Fleming 20, 1300, Wavre, Belgium. Eleftherios.x.zarkadoulas@gsk.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.
Abstract (Originalsprache)
Background
Herpes zoster (HZ) is common in Finland, leading to long-term postherpetic neuralgia (PHN) especially with ageing. HZ reduces productivity, placing an economic burden on society. An integrated actuarial and macroeconomic model assessed the return on investment of recombinant zoster vaccine (RZV) in Finland for adults ≥ 50 years versus no vaccination.
Methods
A validated economic model determined HZ cases and complications avoided, health gains (quality-adjusted life-years, QALYs), and healthcare cost-savings. Actuarial techniques projected population trends incorporating employment factors. Lost productivity averted through vaccination provided fiscal revenue for the government, and increased gross domestic product (GDP) for society. QALY gains were monetised using 1–3xGDP per QALY. RZV was administered for 20 years, with lifetime impact assessment.
Results
RZV vaccination of around 790,000 50year-olds was estimated to save 3,779 QALYs and €52 million (M) in healthcare costs. Averted productivity losses generated €152 M in fiscal revenue and €367 M in GDP, while vaccination costs were €236 M. From the fiscal perspective, 90% of vaccination costs were offset by fiscal and healthcare cost savings (without considering QALY gains). From the societal perspective, for every €1 invested in vaccination, €2.60–4.10 was saved (depending on QALY value). The benefit-cost ratio (BCR) remained positive across sensitivity analyses. The highest BCRs were achieved when vaccinating adults aged 50 years; or 65 years when excluding productivity benefits.
Conclusion
RZV vaccination in working-age adults yielded economic benefits in Finland, generating €2.60–4.10 for society per €1 invested in vaccination, and with fiscal benefits offsetting 90% of vaccination costs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- GSK, Av. Fleming 20, 1300, Wavre, Belgium. Eleftherios.x.zarkadoulas@gsk.com.
- GSK, Helsinki, Finland.
- Nordic Healthcare Group, Helsinki, Finland.
- Department of Health Sciences, University of Groningen, University Medical Center, Groningen, The Netherlands.
- Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.
- Department of Economics, Econometrics & Finance, University of Groningen, Groningen, The Netherlands.
Förderung
- GSK
Zitieren
APA
Zarkadoulas, E., Raunio, H., Mauno, V., Postma, M., & Kotsopoulos, N. (2026). Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model. The European Journal of Health Economics. https://doi.org/10.1007/s10198-026-01949-w
Vancouver
Zarkadoulas E, Raunio H, Mauno V, Postma M, Kotsopoulos N. Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model. The European Journal of Health Economics. 2026. doi:10.1007/s10198-026-01949-w
BibTeX
@article{Zarkadoulas2026,
author = {Zarkadoulas, Eleftherios and Raunio, Hanna and Mauno, Vivi and Postma, Maarten and Kotsopoulos, Nikolaos},
title = {Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial model},
journal = {The European Journal of Health Economics},
year = {2026},
doi = {10.1007/s10198-026-01949-w}
}
EUVIMED